-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Allergic Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Allergic Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Allergic Asthma Drug Details: Acloproxalap (ADX-629) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Typhella in Typhoid Fever
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Typhella in Typhoid Fever report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Typhella in Typhoid Fever Drug Details: Typhella is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Sicca Syndrome (Sjogren)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Sicca Syndrome (Sjogren) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Sicca Syndrome (Sjogren) Drug Details: Acloproxalap (ADX-629) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Atopic Dermatitis (Atopic Eczema) Drug Details: Acloproxalap (ADX-629)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Acloproxalap in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Acloproxalap in Chronic Cough report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acloproxalap in Chronic Cough Drug Details: Acloproxalap (ADX-629) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagtociclib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagtociclib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagtociclib in Triple-Negative Breast Cancer (TNBC) Drug Details: Tagtociclib (PF-07104091)...
-
Product Insights
NewRetinitis Pigmentosa (Retinitis) – Drugs In Development, 2024
Empower your strategies with our Retinitis Pigmentosa (Retinitis) – Drugs In Development, 2024 report and make more profitable business decisions. Retinitis pigmentosa refers to a group of diseases that cause a slow but progressive loss of vision. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance, and x-linked inheritance. The Retinitis Pigmentosa (Retinitis) drugs in development market research report provide comprehensive information on...
-
Product Insights
NewAlcoholic Hepatitis – Drugs In Development, 2024
Empower your strategies with our Alcoholic Hepatitis – Drugs In Development, 2024 report and make more profitable business decisions. Alcoholic hepatitis is inflammation of the liver caused by excessive alcohol consumption over a long period of time. Symptoms include changes in appetite, dry mouth, weight loss, yellowing of the skin or eyes (jaundice), fever, and fatigue. Risk factors include alcohol use, obesity, and genetic factors. Treatment includes corticosteroids and liver transplant. The Alcoholic Hepatitis drugs in development market research report provide...
-
Product Insights
NewAllergic Conjunctivitis – Drugs In Development, 2024
Empower your strategies with our Allergic Conjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) becomes swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye, and stringy eye discharge. Treatment includes antihistamine...
-
Product Insights
NewChronic Cough – Drugs In Development, 2024
Empower your strategies with our Chronic Cough – Drugs In Development, 2024 report and make more profitable business decisions. Chronic cough is a respiratory disorder, characterized by a persistent cough lasting at least eight weeks or longer. Coughing is a natural defense mechanism, clearing bronchial secretions and eliminating inhaled foreign particles. Chronic cough can result from various causes, including respiratory infections like bronchitis or pneumonia, gastroesophageal reflux disease (GERD), asthma, and postnasal drip. Understanding and addressing the underlying condition is essential...